• epirubicin
  • Using DOXOrubicin together with epiRUBicin can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. (drugs.com)
  • cardiomyocytes
  • These results led the researchers to hypothesize that inhibition of apoptosis in Doxorubicin-treated cardiomyocytes was due to Bcl-2 acting as an antioxidant enzyme to decrease the amount of ROS, therefore inhibiting the ability of p53 to induce apoptosis. (wikipedia.org)
  • chemotherapeutic
  • Doxorubicin is an effective chemotherapeutic agent against multiple types of malignancies. (wikipedia.org)
  • Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. (wikipedia.org)
  • regimen
  • The rate of this side effect limits the dose of this formulation that can be given as compared with plain doxorubicin in the same treatment regimen, thereby limiting potential substitution. (wikipedia.org)
  • The minimization of this side effect may allow for one-for-one (1:1) substitution with doxorubicin in the same treatment regimen, thereby improving safety with no loss of efficacy. (wikipedia.org)
  • Combination
  • Studies have shown that the overall response (OR) rate, but not overall survival (OS), doubles when doxorubicin was given in combination with cisplatin, IFN, and 5-fluorouracil. (wikipedia.org)
  • drugs
  • You must check to make sure that it is safe for you to take doxorubicin with all of your drugs and health problems. (drugs.com)
  • urine
  • If any of these effects continue or worsen, notify your doctor or pharmacist.Doxorubicin may give a reddish color to your urine, tears, and sweat. (medicinenet.com)
  • type
  • The amount of doxorubicin (liposomal) you will receive depends on many factors, including your height and weight, your general health or other health problems, and the type of cancer you have. (chemocare.com)
  • cancer cells
  • Our goal is to develop a model for the binding, internalization, and tumor-killing dynamics of liposome-enclosed doxorubicin targeted to cancer cells and develop design principles for creating more effective therapeutics. (mit.edu)
  • Doxorubicin works by slowing or stopping the growth of cancer cells. (medicinenet.com)
  • The proposed method of action is that upon administration zoptarelin doxorubicin binds to the LHRH receptor and is subsequently internalized, concentrating the toxic doxorubicin within cancer cells and the small subset of normal tissues, as opposed to the completely systemic distribution observed with untargeted chemotherapeutics. (wikipedia.org)